Fulgent Genetics PE ratio FLGT

Share price divided by earnings per share over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 6.5×; Apr 2023
6-year median: 4.9×
6-year range: 2.9× to 400×
Peer median: 87.7×

Fulgent Genetics has no meaningful PE ratio today: it lost $2.82 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Apr 2023, at 6.5×.

On the days it had one over the last 6 years, its median was 4.9×, from 2.9× in Oct 2022 to 400× in Aug 2020.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	6.5×	3.4×	7.4×
2022	3.4×	2.9×	4.8×
2021	5.2×	4.3×	79.7×
2020	25.8×	20.1×	400×

Against its peers

Companies in Medical - Diagnostics & Research nearest Fulgent Genetics' size, closest first, today.

Company	PE ratio
FLGTFulgent Genetics	n/m
NRCNRC Health	87.7×
ICCCImmucell	128×
CDNACareDx	33.4×
VCYTVeracyte	34.2×
BLLNBillionToOne	166×
Peer median	87.7×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Fulgent Genetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.